ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer

Oncotarget

Volumn 6, Issue 8, 2015, Pages 5860-5876

  Zou, Peng ^a,b   Zhang, Junru ^a   Xia, Yiqun ^a   Kanchana, Karvannan ^a   Guo, Guilong ^a   Chen, Wenbo ^a   Huang, Yi ^a   Wang, Zhe ^a   Yang, Shulin ^b   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Curcumin analog; ER stress; Gastric cancer; JNK; ROS

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CURCUMIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; KI 67 ANTIGEN; PROTEIN MDM2; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WZ 35; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM STRESS; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL GROWTH; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CURCUMIN; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925637189     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3333     Document Type: Article

References (51)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127(12):2893-2917.
2. Mullen JT and Ryan DP. Neoadjuvant chemotherapy for gastric cancer: what are we trying to accomplish? Annals of surgical oncology. 2014; 21(1):13-15.
3. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J and Fleig WE. Chemotherapy for advanced gastric cancer. The Cochrane database of systematic reviews. 2010; (3):CD004064.
4. Graziano F, Catalano V, Lorenzini P, Giacomini E, Sarti D, Fiorentini G, De Nictolis M, Magnani M and Ruzzo A. Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy. The pharmacogenomics journal. 2014.
5. Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C and Rougier P. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2005; 16(9):1488-1497.
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(31):4991-4997.
7. Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB. Bioavailability of curcumin: problems and promises. Molecular pharmaceutics. 2007; 4(6):807-818.
8. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer research. 2001; 21(4B):2895-2900.
9. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(14):4491-4499.
10. Heger M, van Golen RF, Broekgaarden M and Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacological reviews. 2014; 66(1):222-307.
11. Ye M, Zhang J, Miao Q and Yao L. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer letters. 2014.
12. Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A, Mukhjerjee S and Das T. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/beta-catenin negative feedback loop. Stem cell research & therapy. 2014; 5(5):116.
13. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ and Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(20):6847-6854.
14. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV and Sarkar FH. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini reviews in medicinal chemistry. 2010; 10(5):372-387.
15. Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J, Zhao Y, Li X and Yang S. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorganic & medicinal chemistry. 2009; 17(6):2623-2631.
16. Lei K and Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(5):2432-2437.
17. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004; 303(5660):1010-1014.
18. Wang L, Song R, Shen Y, Sun Y, Gu Y, Shu Y and Xu Q. Targeting sarcoplasmic/endoplasmic reticulum Ca(2)+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Molecular cancer therapeutics. 2011; 10(3):461-471.
19. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL and Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes & development. 1998; 12(7):982-995.
20. Chen W, Zhao Z, Li L, Wu B, Chen SF, Zhou H, Wang Y and Li YQ. Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway. Free radical biology & medicine. 2008; 45(1):60-72.
21. Moon DO, Park SY, Choi YH, Ahn JS and Kim GY. Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: involvement of ROS-dependent ER-stress. Biochemical pharmacology. 2011; 82(11):1641-1650.
22. Chang Z, Xing J and Yu X. Curcumin induces osteosarcoma MG63 cells apoptosis via ROS/Cyto-C/Caspase-3 pathway. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(1):753-758.
23. Han X, Xu B, Beevers CS, Odaka Y, Chen L, Liu L, Luo Y, Zhou H, Chen W, Shen T and Huang S. Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis. 2012; 33(4):868-875.
24. Leontieva OV and Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging. 2011; 3(11):1078-1091.
25. Halasi M, Wang M, Chavan TS, Gaponenko V, Hay N and Gartel AL. ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. The Biochemical journal. 2013; 454(2):201-208.
26. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ and et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71(12):3813-3818.
27. Martin KR and Barrett JC. Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Human & experimental toxicology. 2002; 21(2):71-75.
28. Boonstra J and Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 2004; 337:1-13.
29. Yen CC, Hsiao CD, Chen WM, Wen YS, Lin YC, Chang TW, Yao FY, Hung SC, Wang JY, Chiu JH, Wang HW, Lin CH, Chen TH, Chen PC, Liu CL, Tzeng CH, et al. Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition. Oncotarget. 2014; 5(3):716-725.
30. Behrend L, Henderson G and Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochemical Society transactions. 2003; 31(Pt 6):1441-1444.
31. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer metastasis reviews. 2006; 25(4):695-705.
32. Trachootham D, Alexandre J and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009; 8(7):579-591.
33. Nogueira V and Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(16):4309-4314.
34. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer cell. 2006; 10(3):175-176.
35. Montero AJ and Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs. 2011; 71(11):1385-1396.
36. Liao YJ, Bai HY, Li ZH, Zou J, Chen JW, Zheng F, Zhang JX, Mai SJ, Zeng MS, Sun HD, Pu JX and Xie D. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell death & disease. 2014; 5:e1137.
37. Vrablic AS, Albright CD, Craciunescu CN, Salganik RI and Zeisel SH. Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2001; 15(10):1739-1744.
38. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, Piette J, Linehan C, Gupta S, Samali A and Agostinis P. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell death and differentiation. 2012; 19(11):1880-1891.
39. Elbling L, Weiss RM, Teufelhofer O, Uhl M, Knasmueller S, Schulte-Hermann R, Berger W and Micksche M. Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2005; 19(7):807-809.
40. Khan HY, Zubair H, Faisal M, Ullah MF, Farhan M, Sarkar FH, Ahmad A and Hadi SM. Plant polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: a mechanism for cancer chemopreventive action. Molecular nutrition & food research. 2014; 58(3):437-446.
41. Gan FF, Kaminska KK, Yang H, Liew CY, Leow PC, So CL, Tu LN, Roy A, Yap CW, Kang TS, Chui WK and Chew EH. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antioxidants & redox signaling. 2013; 19(11):1149-1165.
42. Esterbauer H, Schaur RJ and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free radical biology & medicine. 1991; 11(1):81-128.
43. Ray PD, Huang BW and Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cellular signalling. 2012; 24(5):981-990.
44. Zhou H, Shen T, Shang C, Luo Y, Liu L, Yan J, Li Y and Huang S. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget. 2014; 5(20):10140-10150.
45. Boyce M and Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell death and differentiation. 2006; 13(3):363-373.
46. Schroder M and Kaufman RJ. ER stress and the unfolded protein response. Mutation research. 2005; 569(1-2):29-63.
47. Yoshida H, Matsui T, Yamamoto A, Okada T and Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001; 107(7):881-891.
48. Shi JM, Bai LL, Zhang DM, Yiu A, Yin ZQ, Han WL, Liu JS, Li Y, Fu DY and Ye WC. Saxifragifolin D induces the interplay between apoptosis and autophagy in breast cancer cells through ROS-dependent endoplasmic reticulum stress. Biochemical pharmacology. 2013; 85(7):913-926.
49. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP and Ron D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes & development. 2004; 18(24):3066-3077.
50. Ma J, Qiu Y, Yang L, Peng L, Xia Z, Hou LN, Fang C, Qi H and Chen HZ. Desipramine induces apoptosis in rat glioma cells via endoplasmic reticulum stress-dependent CHOP pathway. Journal of neuro-oncology. 2011; 101(1):41-48.
51. Wali VB, Bachawal SV and Sylvester PW. Endoplasmic reticulum stress mediates gamma-tocotrienol-induced apoptosis in mammary tumor cells. Apoptosis: an international journal on programmed cell death. 2009; 14(11):1366-1377.